newsfilter
← Latest News
Business Wire·

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

DiaMedica planning to conduct a rat pharmacokinetic and activity study, which it believes will address FDA-requested data for a preeclampsia IND DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage